The rapid induction of liver glycerophosphate acyltransferase in mice by clofibrate, a hypolipidemic agent.
Administration of clofibrate to adult mice (20-25 mg of clofibrate/day) increased liver glycerophosphate acyltransferase (EC 2.3.1.15) activity by 2.3-fold within 24 h. This increased glycerophosphate acyltransferase activity was mainly localized in the liver microsomal fraction. Three other hypolipidemic drugs, i.e. Bezafibrate (Boehringer Mannheim Co.), Gemfibrozil (Warner-Lambert Co.) and Wy-14,643 (Wyeth Laboratories), when fed to mice, also increased the liver glycerophosphate acyltransferase activity by 2-3-fold in 24 h. Simultaneous administration of inhibitors of protein biosynthesis, such as cycloheximide or actinomycin D completely abolished such stimulation of liver glycerophosphate acyltransferase by clofibrate.
D000217:Acyltransferases / Q000235:genetics*; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D002994:Clofibrate / Q000494:pharmacology*; D004790:Enzyme Induction; D005992:Glycerol-3-Phosphate O-Acyltransferase / Q000235:genetics*; D008099:Liver / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology
D000924:Anticholesteremic Agents; D000217:Acyltransferases; D005992:Glycerol-3-Phosphate O-Acyltransferase; D002994:Clofibrate